Compare MQ & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | NVCR |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2015 |
| Metric | MQ | NVCR |
|---|---|---|
| Price | $3.97 | $17.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $5.36 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 4.5M | 1.4M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | $624,884,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $16.89 | $7.72 |
| Revenue Next Year | $16.36 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.25 | 8.28 |
| 52 Week Low | $3.70 | $9.82 |
| 52 Week High | $7.04 | $18.92 |
| Indicator | MQ | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 54.86 |
| Support Level | $3.81 | $12.66 |
| Resistance Level | $4.30 | $18.80 |
| Average True Range (ATR) | 0.19 | 1.05 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 34.37 | 62.75 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.